https://www.investing.com/news/company-news/telix-pharmaceuticals-plans-nasdaq-listing-93CH-3446532
InvestingPro Insights
Telix Pharmaceuticals Limited (ASX: TLX), as it prepares for its Nasdaq debut, presents a compelling profile according to recent data from InvestingPro. With a market capitalization of approximately $20.12 billion USD and a P/E ratio of 11.56, the company appears to be valued favorably in relation to its earnings. Adjusted for the last twelve months as of Q4 2023, the P/E ratio is slightly lower at 11.28, indicating a stable earnings perspective relative to its share price.
InvestingPro Tips suggest that Telix Pharmaceuticals is expected to see net income growth this year, which could be a positive signal for potential investors looking at the long-term viability of the company. Moreover, the company is trading at a high EBITDA valuation multiple, which may reflect market optimism regarding its future profitability and growth potential.
Financially, the company has demonstrated solid revenue growth, with a 12.72% increase in the last twelve months as of Q4 2023. The quarterly revenue growth for Q4 2023 was even more impressive at 32.25%. These figures underscore Telix's strong financial performance and potential for continued expansion in the biopharmaceutical sector.
- Forums
- ASX - By Stock
- TLX
- Ann: Telix Reports Q1 2024 Financial Performance
Ann: Telix Reports Q1 2024 Financial Performance, page-24
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$19.94 |
Change
0.010(0.05%) |
Mkt cap ! $6.672B |
Open | High | Low | Value | Volume |
$20.10 | $20.54 | $19.79 | $50.61M | 2.514M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2874 | $19.94 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.95 | 55 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2874 | 19.940 |
2 | 237 | 19.860 |
1 | 1000 | 19.840 |
2 | 655 | 19.830 |
1 | 11385 | 19.820 |
Price($) | Vol. | No. |
---|---|---|
19.950 | 55 | 1 |
20.000 | 5884 | 2 |
20.040 | 5834 | 2 |
20.080 | 17219 | 2 |
20.090 | 500 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online